

CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

NCT05827835

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Zhejiang University
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (18)

- Provision of signed and dated informed consent form (ICF)
- Male or female, older than 18 years (including 18 years)
- Anticipated survival time more than 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status d2
- According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphocytic Leukemia and Acute Myeloid Leukemia (2016. v1), patients diagnosed as CD7+ALL and AML
- ... and 13 more (see full listing online)

Exclusion (13)

- Patients with the history of epilepsy or other CNS disease
- Pregnant or breastfeeding
- Active infection with no cure
- Patients with prolonged QT interval time or severe heart disease
- Have experienced hypersensitivity or intolerance to any drug used in this study
- ... and 8 more (see full listing online)

Locations (1 total)

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China